TG Therapeutics (NASDAQ:TGTX) Receives Buy Rating from HC Wainwright

TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reissued by HC Wainwright in a note issued to investors on Monday,Benzinga reports. They presently have a $70.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 26.24% from the stock’s current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, May 1st. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a research report on Monday, June 22nd. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $58.60.

TG Therapeutics Stock Up 4.0%

Shares of TG Therapeutics stock traded up $2.14 during trading on Monday, hitting $55.45. 837,236 shares of the stock traded hands, compared to its average volume of 2,223,743. The stock has a market cap of $8.49 billion, a P/E ratio of 19.39, a PEG ratio of 2.18 and a beta of 1.60. The company has a fifty day moving average price of $43.98 and a two-hundred day moving average price of $35.41. TG Therapeutics has a twelve month low of $25.28 and a twelve month high of $57.38. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.12 and a current ratio of 5.81.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The firm had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter in the previous year, the business posted $0.03 earnings per share. The business’s quarterly revenue was up 69.5% compared to the same quarter last year. Equities research analysts predict that TG Therapeutics will post 1.51 EPS for the current fiscal year.

Institutional Investors Weigh In On TG Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of TGTX. Danske Bank A S acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at $25,000. EverSource Wealth Advisors LLC boosted its holdings in shares of TG Therapeutics by 51.9% in the first quarter. EverSource Wealth Advisors LLC now owns 1,068 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 365 shares during the period. Hantz Financial Services Inc. increased its holdings in TG Therapeutics by 82.7% during the 4th quarter. Hantz Financial Services Inc. now owns 1,237 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 560 shares in the last quarter. Truvestments Capital LLC boosted its holdings in TG Therapeutics by 172.4% during the fourth quarter. Truvestments Capital LLC now owns 1,621 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 1,026 shares during the last quarter. Finally, Kemnay Advisory Services Inc. acquired a new position in shares of TG Therapeutics during the 4th quarter worth about $52,000. 58.58% of the stock is owned by institutional investors.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.